Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 23: OCT Vs IVUS Vs Angiography Guidance
Author(s): Gregg Stone Added: 7 months ago
ESC 2023 — Dr Gregg Stone (Icahn School of Medicine at Mount Sinai, US) shares the findings from a real-time updated network meta-analysis comparing OCT, IVUS and Angiography guidance in percutaneous coronary intervention (PCI) procedures. The OCTOBER and ILUMIEN IV randomised trials both studied OCT-guided versus angiography-guided PCI. This analysis compared the overall effects of… View more

Intervention
SUGAR: Amphilimus-eluting Stents VS Zotarolimus-eluting Stents in Patients With DB
Author(s): Rafael Romaguera Added: 2 years ago
In this short interview, Dr Rafael Romaguera (University of Barcelona, SP) discusses the findings from the SUGAR trial.This randomized head-to-head trial aimed to compare Cre8 EVO stents to a contemporary drug-eluting stent (DES) in patients with diabetes (DM) and coronary artery disease. The trial, first presented at TCT 2021, demonstrated that Cre8 EVO stents were non-inferior to Resolute Onyx… View more

Prevention & Chronic Conditions
CRT 24: The ABSORB Trial
Author(s): David Power Added: 4 weeks ago
CRT 24 - We are joined in this short virtual interview by investigator, Dr David Power (Mount Sinai Hospital, US) to discuss the latest findings from the ABSORB trial series, revealed in 2024 at the CRT conference.ABSORB III is a prospective, randomized, single-blind, multicenter trail aiming to support the pre-market approval of the Absorb bioresorbable vascular scaffold (Abbott) for the… View more

Vascular Disease and Surgery

Intervention
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 5 months ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
TCT 23: 5 Trials That Changed My Practice
Author(s): Mirvat Alasnag Added: 5 months ago
TCT 23 - We are joined by Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, SA) for an insightful summary of the late-breaking trials that are expected to have an impact on interventional science and clinical practice. Trials covered in detail include: Agent IDE ALIGN-AR PARTNER 3 EVOLUT Low-Risk TRISCEND Recorded remotely from Jeddah, 2023. Editor: Jordan Rance Video Specialist:… View more

Intervention
Author(s): Rhian E Davies , J Dawn Abbott Added: 3 years ago
Percutaneous Coronary Intervention for Clinical Syndromes Stable Angina The primary benefit of percutaneous coronary intervention (PCI) over medical therapy in patients with stable angina is the improved quality of life. The PCI in stable angina (ORBITA) trial was the first sham-controlled trial of PCI where 200 medically optimized patients with single vessel disease were randomized to PCI or… View more

Intervention
Author(s): Bill D Gogas , Jun-Jie Zhang , Shao-Liang Chen Added: 3 years ago
The current generation of drug-eluting stents (DES) that are clinically available in the US represent significant advancements compared to angioplasty, bare metal stents, and the first generation of DES. The Xience everolimus-eluting stents (Abbott Vascular), Promus everolimus-eluting stents (Boston Scientific) and Resolute zotarolimus-eluting stents (Medtronic) demonstrate the optimal balance of… View more

Intervention
View from the Thoraxcenter: TCT 23 Late-breaking Science Preview
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 6 months ago
What's hot at TCT 2023? In this episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the late-breaking data presented at TCT 2023. With their dynamic analysis, these anticipated trials are placed in context, highlighting the real-world implications tied to the data releases. Top trials covered: 00:31 - 02:12: PARTNER 3 Low… View more

Intervention
ESC 23: Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
Author(s): Mirvat Alasnag , Khaled Al-Shaibi Added: 7 months ago
ESC 23 — We are joined by Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (The King Fahd Armed Forces Hospital, SA) for an insightful wrap-up of the third day of ESC Congress 2023. New data releases covered in detail include: ILUMIEN IV OCTIVUS OCTOBER OCT Vs IVUS Vs Angiography Guidance Meta-analysis MULTISTARS-AMI ATTRibute Recorded on-site at ESC Congress 2023, Amsterdam. Editors: Mirjam Boros… View more

Intervention
Feasibility, Safety, and Clinical Performance of Self-apposing Stents for Left Main Stenosis
Author(s): Krzysztof Pujdak , Jan Kähler , Marc Werner Added: 3 years ago
Significant stenosis of the left main (LM) coronary artery is observed in 7% of coronary angiographies.1 Coronary artery bypass grafting has traditionally been the treatment of choice. In recent years, percutaneous coronary intervention (PCI) has evolved as an alternative, especially for low and intermediate SYNTAX score patients.2 However, during PCI of bifurcation lesions, approximately 50% of… View more

Intervention